{
    "id": 25102,
    "fullName": "KMT2A - EP300",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KMT2A-EP300 results from the fusion of KMT2A and EP300 (PMID: 20980053). KMT2A-EP300 has been identified in acute myeloid leukemia (PMID: 20980053), but not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 6424,
                    "pubMedId": 20980053,
                    "title": "Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20980053"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4297,
        "geneSymbol": "KMT2A",
        "terms": [
            "KMT2A",
            "ALL-1",
            "CXXC7",
            "HRX",
            "HTRX1",
            "MLL",
            "MLL1",
            "MLL1A",
            "TRX1",
            "WDSTS"
        ]
    },
    "variant": "KMT2A - EP300",
    "createDate": "08/03/2016",
    "updateDate": "01/13/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2033,
                "geneSymbol": "EP300",
                "terms": [
                    "EP300",
                    "KAT3B",
                    "MKHK2",
                    "p300",
                    "RSTS2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11494,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 inhibited growth of a primary acute myeloid sample harboring KMT2A-EP300 in culture (PMID: 25817203).",
            "molecularProfile": {
                "id": 25868,
                "profileName": "KMT2A - EP300"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9548,
                    "pubMedId": 25817203,
                    "title": "Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25817203"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25868,
            "profileName": "KMT2A - EP300",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}